BCR-ABL delays apoptosis upstream of procaspase-3 activation

Laurence Dubrez, Béatrice Eymin, Olivier Sordet, Nathalie Droin, Ali G. Turhan, Eric Solary

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    99 Citations (Scopus)

    Résumé

    The p210(bcr-abl) protein was shown to inhibit apoptosis induced by DNA damaging agents. Apoptotic DNA fragmentation is delayed in the bcr-abl+ K562 and KCL-22 compared with the bcr-abl- U937 and HL-60 cell lines when treated with etoposide concentrations that induce similar DNA damage in the four cell lines. By the use of a cell-free system, we show that nuclei from untreated cells that express p210(bcr-abl) remain sensitive to apoptotic DNA fragmentation induced by triton-soluble extracts from p210(bcr-abl-) cells treated with etoposide. In the four tested cell lines, apoptotic DNA fragmentation is associated with a decreased expression of procaspase-3 (CPP32/Yama/apopain) and its cleavage into a p17 active fragment, whereas the long isoform of procaspase-2 (ICH-1L) remains unchanged and the poly(adenosine diphosphate-ribose)polymerase protein is cleaved. These events are delayed in bcr-abl+ compared with bcr-abl- cell lines. The role of p210(bcr-abl) in this delay is confirmed by comparing the effect of etoposide on the granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent UT7 cells and the bcr-abl-transfected GM-CSF-independent UT7/9 clone. We conclude that the cytosolic pathway that leads to apoptotic DNA fragmentation in etoposide-treated leukemic cells is delayed upstream of procaspase-3- mediated events in bcr-abl+ cell lines.

    langue originaleAnglais
    Pages (de - à)2415-2422
    Nombre de pages8
    journalBlood
    Volume91
    Numéro de publication7
    Les DOIs
    étatPublié - 1 avr. 1998

    Contient cette citation